CompareMarketResearchRequest a sample
Home / Healthcare / CRISPR and Cas Gene

Healthcare · Market report

CRISPR and Cas Gene Market Size, Share and Forecast 2026-2036

The global CRISPR and cas gene market is worth USD 2.9 bn in 2026 and is forecast to reach USD 10.1 bn by 2036, growing at a 13.5% CAGR. United States is the largest country market and Cas enzymes and kits is the largest by product segment.

USD 2.9 bnMarket size 2026
USD 10.1 bnForecast 2036
13.5%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global CRISPR and cas gene market is worth USD 2.9 bn in 2026 and is forecast to reach USD 10.1 bn by 2036, growing at a 13.5% CAGR. United States is the largest country market and Cas enzymes and kits is the largest by product segment.

ScopeCRISPR and Cas genome-editing products for research and drug development: Cas enzymes and kits, guide RNAs and screening libraries, delivery reagents and contract editing and screening services, excluding approved therapies.
IndustryHealthcare
Value 2025USD 2.5 bn
Value 2026USD 2.9 bn
Value 2036USD 10.1 bn
CAGR 2026-203613.5%
Volume 20261,311 thousand orders
Volume 20364,651 thousand orders
Average price 2026USD 2,174 per order
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

CRISPR and Cas Gene market size and forecast, 2026-2036

Exhibit 1The global CRISPR and cas gene market is forecast to grow from USD 2.9 bn in 2026 to USD 10.1 bn by 2036, more than triplingGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 13.5%
CRISPR and Cas Gene market value, 2025 to 2036Market value by year. 2025: USD 2.5 bn; 2026: USD 2.9 bn; 2027: USD 3.2 bn; 2028: USD 3.7 bn; 2029: USD 4.2 bn; 2030: USD 4.7 bn; 2031: USD 5.4 bn; 2032: USD 6.1 bn; 2033: USD 6.9 bn; 2034: USD 7.8 bn; 2035: USD 8.9 bn; 2036: USD 10.1 bn. Compound annual growth rate 2026 to 2036: 13.5%.20252.9 bn20265.4 bn203110.1 bn203613.5% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 2.9 bn
2027USD 3.2 bn
2028USD 3.7 bn
2029USD 4.2 bn
2030USD 4.7 bn
2031USD 5.4 bn
2032USD 6.1 bn
2033USD 6.9 bn
2034USD 7.8 bn
2035USD 8.9 bn
2036USD 10.1 bn

CRISPR and Cas Gene market segmentation

By product

Exhibit 2Cas enzymes and kits is the largest segment by product, with 34.0% of 2026 revenueEstimated share of 2026 global revenue, by product
CRISPR and Cas Gene market share by product, 2026Share of 2026 revenue by product. Cas enzymes and kits: 34.0%; Guide RNAs and libraries: 28.0%; Editing and screening services: 22.0%; Delivery reagents: 16.0%.Cas enzymes and kits34.0%Guide RNAs and libraries28.0%Editing and screening services22.0%Delivery reagents16.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Cas enzymes and kits34.0%29.6%USD 969 mn11.9%
Guide RNAs and libraries28.0%26.6%USD 798 mn12.9%
Editing and screening services22.0%27.2%USD 627 mn15.9%
Delivery reagents16.0%16.6%USD 456 mn13.9%

By end user

Exhibit 3Pharmaceutical and biotechnology companies adds the most revenue by end user, growing from USD 1.3 bn in 2026 to USD 5.1 bn by 2036Estimated revenue in USD by end user, 2026 and 2036 forecast
CRISPR and Cas Gene market by end user, 2026 and 2036Revenue by end user in 2026 and 2036. Pharmaceutical and biotechnology companies: USD 1.3 bn in 2026, USD 5.1 bn in 2036, change +292%; Academic and research institutes: USD 1.1 bn in 2026, USD 3.1 bn in 2036, change +187%; Contract research organisations: USD 456 mn in 2026, USD 1.9 bn in 2036, change +309%.20262036 forecastChangePharmaceutical and biotechnology companies+292%1.3 bn5.1 bnAcademic and research institutes+187%1.1 bn3.1 bnContract research organisations+309%456 mn1.9 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Pharmaceutical and biotechnology companies46.0%50.8%USD 1.3 bn14.6%
Academic and research institutes38.0%30.8%USD 1.1 bn11.1%
Contract research organisations16.0%18.4%USD 456 mn15.1%

By system type

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Cas9 nucleases56.0%50.0%USD 1.6 bn12.2%
Cas12 systems18.0%20.0%USD 513 mn14.7%
Base and prime editors14.0%20.0%USD 399 mn17.6%
Other systems12.0%10.0%USD 342 mn11.4%

By application

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Therapeutics44.0%50.0%USD 1.3 bn15.0%
Research tools30.0%26.0%USD 855 mn11.9%
Agricultural biotech14.0%14.0%USD 399 mn13.5%
Diagnostics12.0%10.0%USD 342 mn11.4%

By delivery

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Viral vectors40.0%38.0%USD 1.1 bn12.9%
Lipid nanoparticles30.0%34.0%USD 855 mn14.9%
Electroporation20.0%17.0%USD 570 mn11.7%
Other methods10.0%11.0%USD 285 mn14.6%

Top 25 countries for CRISPR and cas gene by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 89.0% of 2026 revenue and the 25 countries below together hold 97.2%.

Exhibit 4United States is the largest country market at USD 1.2 bn in 2026, and the three largest countries hold 63.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
CRISPR and Cas Gene market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 1.2 bn, 42.0%; China: USD 428 mn, 15.0%; Germany: USD 171 mn, 6.0%; United Kingdom: USD 171 mn, 6.0%; Japan: USD 171 mn, 6.0%; South Korea: USD 86 mn, 3.0%; France: USD 86 mn, 3.0%; Canada: USD 86 mn, 3.0%; India: USD 71 mn, 2.5%; Switzerland: USD 71 mn, 2.5%.United States1.2 bn 42.0%China428 mn 15.0%Germany171 mn 6.0%United Kingdom171 mn 6.0%Japan171 mn 6.0%South Korea86 mn 3.0%France86 mn 3.0%Canada86 mn 3.0%India71 mn 2.5%Switzerland71 mn 2.5%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 1.2 bn42.0%USD 4.2 bn13.3%
2ChinaUSD 428 mn15.0%USD 1.8 bn15.3%
3GermanyUSD 171 mn6.0%USD 546 mn12.3%
4United KingdomUSD 171 mn6.0%USD 566 mn12.7%
5JapanUSD 171 mn6.0%USD 526 mn11.9%
6South KoreaUSD 86 mn3.0%USD 324 mn14.2%
7FranceUSD 86 mn3.0%USD 273 mn12.3%
8CanadaUSD 86 mn3.0%USD 283 mn12.7%
9IndiaUSD 71 mn2.5%USD 324 mn16.3%
10SwitzerlandUSD 71 mn2.5%USD 233 mn12.6%
11NetherlandsUSD 44 mn1.6%USD 153 mn13.2%
12AustraliaUSD 40 mn1.4%USD 136 mn13.2%
13BelgiumUSD 28 mn1.0%USD 97 mn13.2%
14SwedenUSD 25 mn0.9%USD 87 mn13.1%
15SingaporeUSD 19 mn0.7%USD 75 mn14.5%
16TaiwanUSD 15 mn0.5%USD 57 mn14.3%
17DenmarkUSD 12 mn0.4%USD 42 mn13.2%
18IsraelUSD 10 mn0.4%USD 35 mn13.2%
19SpainUSD 8.6 mn0.3%USD 29 mn13.1%
20ItalyUSD 7.1 mn0.2%USD 24 mn13.0%
21BrazilUSD 5.7 mn0.2%USD 22 mn14.6%
22AustriaUSD 5.7 mn0.2%USD 19 mn12.9%
23IrelandUSD 4.3 mn0.1%USD 15 mn13.5%
24PolandUSD 4.0 mn0.1%USD 15 mn14.3%
25MexicoUSD 3.1 mn0.1%USD 12 mn14.5%
Rest of worldUSD 81 mn2.8%USD 282 mn13.3%
Exhibit 5United States and China account for 59% of the USD 7.3 bn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
CRISPR and Cas Gene market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 2.9 bn. United States: +USD 3.0 bn; China: +USD 1.3 bn; United Kingdom: +USD 395 mn; Germany: +USD 375 mn; Japan: +USD 355 mn; 20 other countries: +USD 1.6 bn; Rest of world: +USD 201 mn. Market value 2036: USD 10.1 bn.Market value 20262.9 bnUnited States+3.0 bnChina+1.3 bnUnited Kingdom+395 mnGermany+375 mnJapan+355 mn20 other countries+1.6 bnRest of world+201 mnMarket value 203610.1 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • Thermo Fisher Scientific
  • Merck KGaA
  • Danaher (IDT)
  • Revvity

Group 2: Regional and specialist players

  • GenScript
  • Synthego
  • Lonza
  • Takara Bio
  • New England Biolabs
  • Agilent Technologies
  • ToolGen
  • Charles River Laboratories

Group 3: Emerging and niche players

  • OriGene
  • Cellecta
  • Ubigene Biosciences
  • Applied StemCell

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the CRISPR and cas gene market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 13.5% is calculated from the resulting values.

The market is divided by product, by end user, by system type, by application, by delivery. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the CRISPR and cas gene market?

The global CRISPR and cas gene market is estimated at USD 2.5 bn in 2025 and USD 2.9 bn in 2026.

How fast will the CRISPR and cas gene market grow?

It is forecast to reach USD 10.1 bn by 2036, a compound annual growth rate of 13.5% from 2026, an increase of USD 7.3 bn.

Which country is the largest market for CRISPR and cas gene?

United States is the largest market by revenue at USD 1.2 bn in 2026, 42.0% of the global total. The three largest countries together hold 63.0%.

Which country is growing fastest?

Among the ten largest markets, India is growing fastest at 16.3% a year from 2026 to 2036.

Which CRISPR and cas gene segment is largest?

In the by product split, Cas enzymes and kits is the largest segment with 34.0% of 2026 revenue.

Who are the leading CRISPR and cas gene companies?

Global leaders include Thermo Fisher Scientific, Merck KGaA, Danaher (IDT), Revvity.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Breast Cancer Grading Tools CRISPR-Integrated Gene Editing Delivery Devices →

All Healthcare markets →

Request a sample